Cladribine (oral) and Daunorubicin and cytarabine liposome Intravenous
Determining the interaction of Cladribine (oral) and Daunorubicin and cytarabine liposome Intravenous and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Using cladribine together with DAUNOrubicin liposomal may increase the risk of serious infections. Talk to your doctor if you have any questions or concerns. Your doctor may already be aware of the risks, but has determined that this is the best course of treatment for you and has taken appropriate precautions and is monitoring you closely for any potential complications. Contact your doctor immediately if you develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:GENERALLY AVOID: The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (greater than 10 mg/day to 1 mg/kg/day, whichever is less, of prednisone or equivalent for more than 2 weeks), and long-term topical or inhaled corticosteroids.
MANAGEMENT: Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.
Generic Name: cladribine
Brand name: Mavenclad, Leustatin
Synonyms: Cladribine
Generic Name: cytarabine liposomal / daunorubicin liposomal
Brand name: Vyxeos
Synonyms: Cytarabine and daunorubicin (liposomal), Daunorubicin and Cytarabine (Liposomal)
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Cladribine (oral)-Daunorubicin citrate
- Cladribine (oral)-Daunorubicin citrate liposome Intravenous
- Cladribine (oral)-Daunorubicin hydrochloride
- Cladribine (oral)-Daunorubicin Intravenous
- Cladribine (oral)-DaunoXome
- Cladribine (oral)-Daurismo
- Daunorubicin and cytarabine liposome Intravenous-Cladribine injection
- Daunorubicin and cytarabine liposome Intravenous-Cladribine Intravenous
- Daunorubicin and cytarabine liposome Intravenous-Cladribine Tablets
- Daunorubicin and cytarabine liposome Intravenous-Claforan
- Daunorubicin and cytarabine liposome Intravenous-Claforan in D5W
- Daunorubicin and cytarabine liposome Intravenous-Claravis